September 18, 2018
These frequent doses of share pricing demise are bottoms to be bought
Rebound territory, the oversold are beckoning!
Pre-open indications: 4 trades
Out and about: Fate Therapeutics (FATE has entered into a collaboration with ONO Pharmaceutical Co., Ltd. for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates. Using FATE’s proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. This transformative approach enables the cost-effective production of cell-based cancer immunotherapies that are uniformly engineered, extensively characterized and homogeneous in composition, and can be consistently and repeatedly mass produced and delivered to patients in an off-the-shelf manner - BUY
RMi provides a pre-market synopsis for the U.S. trading day.
I answer one question, in which company should investors put, keep and commit their money
September 15, 2018
Volume, algorithms, ETFs, enrollments issues and clinical results are indications of volatility - some good and many very bad!
Review daily indicators, factors and trend lines, advance/decline lines of 45 covered companies, pre-open indicator results and volatility and of the % count of decliners versus gainers.
Does momentum’s magnitude so far this month indicate pricing performance by Q3’s end?
Click on the BUY button: http://www.regmedinvestors.com/create-account
September 18, 2018
The sector pops along with the NASDAQ (+0.76%) and the IBB (+1.12%) with extremely low volumes
As I had stated, ““Our” universe should make some better headway after yesterday’s drubbing!”
The real issue is what caused Monday’s downdrafts? The weighting of the rebound after a severe sell-offs reinforces, there is a further concern – trading is the foundation of sentiment!
Pre-open indications: 4 HIT and 0 MISS
Out and about: BioTime (NYSEMKT: BTX) Appoints Brian Culley as CEO
Who is defining the metrics for individual investors and which broker, trader, fund or I-Bank is keeping you notified of the sector and market fluctuations?
RMi’s daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.
September 11, 2018
Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies Thirty-six (36) LPS, four (4) net income and two (2) delayed or incomplete - Intrexon (XON) and MiMedx (MDXG) ... so far of 45 covered companies The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
September 5, 2018
HSGX drops -$1.71 or -61.73% (from yesterday’s close of $2.77) as VCEL gains +$1.85 or +15.88% A “gift” for VCEL, MACI and ... another offering?
August 17, 2018
I maintain as a short-term trading vehicle as there is more historical upside to “eat” through! Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates; .... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%)
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
5 hours 36 min ago
RegMed Investors’ (RMi) closing bell: a strong dose of value
16 hours 14 min ago
RegMed Investors’ (RMi) pre-open: another sector crash too far
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
